AU2002210383A1 - The function of a haptoglobin-haemoglobin receptor and the uses thereof - Google Patents

The function of a haptoglobin-haemoglobin receptor and the uses thereof

Info

Publication number
AU2002210383A1
AU2002210383A1 AU2002210383A AU1038302A AU2002210383A1 AU 2002210383 A1 AU2002210383 A1 AU 2002210383A1 AU 2002210383 A AU2002210383 A AU 2002210383A AU 1038302 A AU1038302 A AU 1038302A AU 2002210383 A1 AU2002210383 A1 AU 2002210383A1
Authority
AU
Australia
Prior art keywords
haptoglobin
haemoglobin
receptor
function
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002210383A
Inventor
Soren Moestrup
Holger J. Moller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProteoPharma Aps
Original Assignee
ProteoPharma Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProteoPharma Aps filed Critical ProteoPharma Aps
Publication of AU2002210383A1 publication Critical patent/AU2002210383A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6445—Haemoglobin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to haptoglobin-haemoglobin (Hp-Hb) complex or a part thereof or a mimic thereof being operably linked to a substance and capable of binding a CD163 receptor. Furthermore, the invention relates to a CD163 variant, membrane bound or soluble, capable of binding at least one haptoglobin-haemoglobin (Hp-Hb) complex, and the use of the Hp-Hb complex and the CD163 receptor for therapy.
AU2002210383A 2000-10-16 2001-10-12 The function of a haptoglobin-haemoglobin receptor and the uses thereof Abandoned AU2002210383A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA200001543 2000-10-16
DKPA200001543 2000-10-16
DKPA200100039 2001-01-11
DKPA200100039 2001-01-11
US27012001P 2001-02-22 2001-02-22
US60/270,120 2001-02-22
PCT/DK2001/000671 WO2002032941A2 (en) 2000-10-16 2001-10-12 The function of a haptoglobin-haemoglobin receptor and the uses thereof

Publications (1)

Publication Number Publication Date
AU2002210383A1 true AU2002210383A1 (en) 2002-04-29

Family

ID=27222446

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002210383A Abandoned AU2002210383A1 (en) 2000-10-16 2001-10-12 The function of a haptoglobin-haemoglobin receptor and the uses thereof

Country Status (10)

Country Link
US (3) US20020155995A1 (en)
EP (1) EP1328297B1 (en)
AT (1) ATE444082T1 (en)
AU (1) AU2002210383A1 (en)
CY (1) CY1110579T1 (en)
DE (1) DE60140069D1 (en)
DK (1) DK1328297T3 (en)
ES (1) ES2334103T3 (en)
PT (1) PT1328297E (en)
WO (1) WO2002032941A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1328297B1 (en) 2000-10-16 2009-09-30 Cytoguide ApS The function of a haptoglobin-haemoglobin receptor and the uses thereof
ATE421886T1 (en) * 2001-03-26 2009-02-15 Therapure Biopharma Inc PRODUCTION OF BLOOD CELLS USING ACTIVATION OF CD163
AU2003243058A1 (en) * 2002-05-27 2003-12-12 Bioceros B.V. Methods for using the cd163 pathway for modulating an immune response
EP1367393A1 (en) * 2002-05-27 2003-12-03 MacroZyme B.V. Methods for using the CD 163 pathway for modulating an immune response
GB0423196D0 (en) * 2004-10-19 2004-11-24 Nat Blood Authority Method
WO2008019186A2 (en) * 2006-05-26 2008-02-14 Temple University - Of The Commonwealth System Of Higher Education Blood monocyte cd163 expression as a biomarker in hiv-1 infection and neuroaids
US20080293623A1 (en) * 2007-04-30 2008-11-27 Nhs Blood And Transplant Enriched haptoglobin polymers for the treatment of disease
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods
GB0917054D0 (en) 2009-09-29 2009-11-11 Cytoguide As Agents, uses and methods
EP2488863A2 (en) 2009-10-12 2012-08-22 Aarhus Universitet Method of prognosis
GB201122325D0 (en) 2011-12-23 2012-02-01 Cytoguide As Novel formulations
CN110256571A (en) * 2018-11-30 2019-09-20 莱尔芙高新技术(上海)有限公司 Recombinant human albumin-hemoglobin β-chain fusion protein
WO2020236952A1 (en) * 2019-05-20 2020-11-26 Ohio State Innovation Foundation Apohemoglobin-haptoglobin complexes and methods of using thereof
MX2022000726A (en) 2019-07-19 2022-02-10 Oncoresponse Inc Immunomodulatory antibodies and methods of use thereof.
KR102254246B1 (en) * 2020-03-23 2021-05-20 큐벳 주식회사 Nucleic acid encoding anti-CD163 antibody or antigen binding fragment thereof, Adenovirus vector comprising the same, and use thereof in the prevention or treatment of African swine fever
US20230381334A1 (en) 2020-09-23 2023-11-30 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
MX2023003377A (en) 2020-09-23 2023-03-31 Ablevia Biotech Gmbh Compound for increasing efficacy of viral vectors.
TW202228784A (en) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 Compound for the sequestration of undesirale anti-peg antibodies in a patient
MX2023003375A (en) 2020-09-23 2023-03-31 Ablevia Biotech Gmbh Compound for increasing the efficacy of factor viii replacement therapy.
CA3192740A1 (en) 2020-09-23 2022-03-31 Oskar SMRZKA Compound for the prevention or treatment of autoantibody-mediated conditions
CA3192735A1 (en) 2020-09-24 2022-03-31 Oskar SMRZKA Compound for the prevention or treatment of myasthenia gravis
EP4276109A1 (en) * 2021-01-05 2023-11-15 Public University Corporation Yokohama City University Biomarker for determining fertility, and determining method using same
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US41177A (en) * 1864-01-05 Tiios
US4177A (en) * 1845-09-02 Phineas bennet
US4061735A (en) * 1973-11-15 1977-12-06 The Green Cross Corporation Haptoglobin in aqueous solution and process for preparing the same
JPS52128205A (en) * 1976-04-16 1977-10-27 Green Cross Corp:The Prophylactic and therapeutic drugs for cerebro-vascular contraction
US5155020A (en) 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
KR0162259B1 (en) * 1989-12-05 1998-12-01 아미 펙터 Chimeric antibody for detection and therapy of infectious and inflammatory lesions
US5204243A (en) 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
US5252348A (en) 1990-10-19 1993-10-12 Univ. Of Florida Research Foundation, Inc. Artificial viral envelopes
WO1996000295A1 (en) 1994-06-27 1996-01-04 The Johns Hopkins University Targeted gene delivery system
US5691197A (en) 1995-02-21 1997-11-25 Tryggvason; Karl Isolated DNA sequence for a novel macrophage receptor with a collagenous domain
AU711702B2 (en) 1995-03-23 1999-10-21 Cambridge University Technical Services Limited Vectors for gene delivery
JPH11512451A (en) * 1995-09-21 1999-10-26 アンダリス、リミテッド Transcytosis vehicles and enhancers for drug delivery
US6479258B1 (en) * 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5972899A (en) 1996-01-25 1999-10-26 New York University Apoptosis induced by Shigella IpaB
JP2000514440A (en) 1996-07-09 2000-10-31 ザ ジョーンズ ホプキンス ユニバーシティー Gene transfer system
US6605699B1 (en) * 1997-01-21 2003-08-12 Human Genome Sciences, Inc. Galectin-11 polypeptides
US6046314A (en) 1997-03-06 2000-04-04 Bristol-Myers Squibb Co. Spα: a novel scavenger receptor cysteine-rich domain-containing polypeptide, and monoclonal antibodies thereto
US5962667A (en) 1997-11-03 1999-10-05 Virginia Commonwealth University Pharmaco-gene delivery in human breast cancer cells
CA2236344A1 (en) * 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
US7144710B2 (en) * 2000-03-28 2006-12-05 Trustees Of Dartmouth College Method for detecting inflammation and inflammatory conditions
EP1328297B1 (en) 2000-10-16 2009-09-30 Cytoguide ApS The function of a haptoglobin-haemoglobin receptor and the uses thereof
GB0917044D0 (en) * 2009-09-29 2009-11-18 Cytoguide As Agents, uses and methods

Also Published As

Publication number Publication date
DK1328297T3 (en) 2010-02-01
CY1110579T1 (en) 2015-04-29
WO2002032941A3 (en) 2002-07-25
PT1328297E (en) 2010-01-04
EP1328297A2 (en) 2003-07-23
US20020155995A1 (en) 2002-10-24
ES2334103T3 (en) 2010-03-05
US20080242843A1 (en) 2008-10-02
ATE444082T1 (en) 2009-10-15
DE60140069D1 (en) 2009-11-12
WO2002032941A2 (en) 2002-04-25
EP1328297B1 (en) 2009-09-30
US20050063951A1 (en) 2005-03-24
WO2002032941A8 (en) 2004-04-29
US9476890B2 (en) 2016-10-25

Similar Documents

Publication Publication Date Title
AU2002210383A1 (en) The function of a haptoglobin-haemoglobin receptor and the uses thereof
WO2005077981A3 (en) Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
DE59906975D1 (en) AQUEOUS REACTIVE SPACHTELMASSEN (I)
WO2002094852A8 (en) Taci-immunoglobulin fusion proteins
WO2004020405A3 (en) Modified transferrin fusion proteins
AU1218000A (en) Polyspecific binding molecules and uses thereof
WO1997032891A3 (en) Conjugate for modifying interactions between proteins
EP2345671B8 (en) Optimized fc variants and methods for their generation
ZA9710098B (en) Halogenopyrimidines.
AU1743201A (en) Receptor binding conjugates
WO1999020747A3 (en) HUMAN CHECKPOINT KINASE, hCDS1, COMPOSITIONS AND METHODS
WO1997045746A3 (en) Prion protein binding proteins and uses thereof
WO2003020759A3 (en) A caspase- 8 binding protein, its preparation and use
AU2001284201A1 (en) Supported catalyst
WO2001076639A3 (en) Chemically-modified myelopoietin conjugates
AU2003258051A1 (en) 5-SUBSTITUTED 7,9-DIFLUORO-5H-CHROMENO(3,4-f)QUINOLINE COMPOUNDS AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS
HK1082510A1 (en) Promoter to il-18bp, its preparation and use
IL152062A0 (en) G protein coupled receptor
AU7427501A (en) Receptor binding molecules